Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. David J Torgerson, senior research fellowa,
  2. Martin Roland, director of research and developmentb
  1. a National Primary Care Research and Development Centre, Centre for Health Economics, University of York, York YO1 5DD
  2. b National Primary Care Research and Development Centre, University of Manchester, Manchester M13 9PL
  1. Correspondence to: Dr Torgerson.

    This is the fourth of an occasional series on the methods of randomised controlled trials

    When patients do not receive their preferred treatment in randomised trials there may be difficulties with patient recruitment and scientific problems with bias.1 For example, bias may occur when patients are aware of a new treatment not available to them and comply poorly with the standard treatment.

    Zelen's design can address these difficulties 2 3 by randomising patients before consent to participate has been sought. Two types of the design exist: double and single consent. In the double consent version patients are initially offered the treatment to which they were randomised; however, if they decline the randomised treatment, they can then be offered alternative therapies—including the experimental treatment. In …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular